← boardnext 2026-11-02next 2026-11-09next 2026-11-23next 2026-12-11next 2026-12-11next 2026-12-28next 2026-12-31next 2027-01-12next 2027-01-15next 2027-02-25next 2027-03-01next 2027-03-09next 2027-03-10next 2027-03-19next 2027-04-22next 2027-04-23next 2027-05-04next 2027-05-31next 2027-05-31next 2027-06-21next 2027-07-22next 2027-07-26next 2027-08-02next 2027-08-23next 2027-08-27next 2027-08-31next 2027-09-22next 2027-10-26next 2027-11-05next 2027-11-11next 2028-01-05next 2028-01-31next 2028-03-24next 2028-03-24next 2028-04-27next 2028-05-30next 2028-09-15next 2028-09-28next 2028-10-18next 2028-10-31next 2029-01-01next 2029-02-06next 2029-02-28next 2029-04-05next 2029-09-24next 2029-12-03next 2030-12-30next 2032-08-30
GSK
GlaxoSmithKlinedistress 1/10 · well-funded / low risk$50.29-1%today-18% from 52w high
Oncology 3Infectious Disease 1Respiratory 1
Lead: Neoplasms
Revenue
$7629M
Liquidity
$3443M
Runway
—
Shares 1y
0%
Price & events
+5.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.9%
1D
-4.7%
1W
-3.4%
1M
-8.8%
3M
+4.1%
6M
+37.2%
1Y
+40.3%
2Y
+56.4%
5Y
+68.9%
All
Overview
- Market Cap
- $217.02B
- Enterprise Value
- $227.60B
- Volume
- 167.14K
- 52 Week Range
- $36.20 – $61.18
- Total Shares
- 4.32B
- Float Shares
- 1.95B
- Short %
- 0.64%
- % Held by Insiders
- 0.06%
- % Held by Institutions
- 18.74%
- RVOL
- 0.04x
- Beta
- 0.30
Pipeline stages · 48 programs
Dostarlimab, Carboplatin, Paclitaxel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pembrolizumab, Dostarlimab, Pemetrexed
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Investigational varicella vaccine_Lot 1, Investigational varicella vaccine_Lot 2, Investig
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
dTpa
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
MMB
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Niraparib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
GSK6097608, Dostarlimab, Cobolimab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Adjuvanted RSVPreF3 vaccine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
FF/UMEC/VI, FF/VI
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
HFA-152a, HFA-134a
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Show all 48 programs · 38 more ▾
TSR-022, Nivolumab, TSR-042
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Camlipixant
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
MenABCWY vaccine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Momelotinib, Glucocorticoids
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Bepirovirsen
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
RTS, S/AS01E vaccine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
GSK3862995B
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Candidate UTI vaccine low dose formulation 1, Candidate UTI vaccine low dose formulation 2
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Mo-Rez, Dostarlimab, Bevacizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
GSK3772701 600 mg, GSK3772701 900 mg, GSK3772701 150 mg
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
VH4524184, Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
GSK4532990
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
HZ/su vaccine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
BLU-5937
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Remzistotug, Dostarlimab, Belrestotug
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Mocertatug rezetecan, Paclitaxel, Pegylated liposomal doxorubicin (PLD)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
GSK5458514
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Ris-Rez, Ivonescimab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
GSK5764227
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Depemokimab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
MMRVNS, MMRV
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Efimosfermin alfa
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
GSK5471713
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Low dose of iNTS-TCV, Full dose of iNTS-TCV, TYPHIBEV
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
IDRX-42, Sunitinib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
GSK4527226
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
GSK5460025
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Belimumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
AltSonflex1-2-3, Menveo, Infanrix hexa
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Oral CAB, IM CAB LA
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
GSK5533524
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Belantamab mafodotin, Cyclophosphamide, Bortezomib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
RSV/hMPV_V low dose vaccine, RSV/hMPV_V medium dose vaccine, RSV/hMPV_V high dose vaccine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
GSK5926371
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Unconjugated belantamab antibody, Belantamab mafodotin, Unconjugated belantamab antibody a
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Fostemsavir, Dolutegravir (DTG)/ Lamivudine (3TC)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Velzatinib, Imatinib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 80 trials · 80 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-11-02 Estimated 50% readout ~2026-12-17 | Phase 2 | Dostarlimab | Neoplasms, Rectal | — | active not recruiting |
| 2026-11-09 Estimated 50% readout ~2026-12-24 | Phase 2 | Pembrolizumab, Dostarlimab, Belrestotug | Lung Cancer, Non-Small Cell | — | active not recruiting |
| 2026-11-23 Estimated 50% readout ~2027-02-06 | Phase 3 | Investigational varicella vaccine, Marketed varicella vaccine, Measles | Chickenpox | — | recruiting |
| 2026-11-23 Estimated 50% readout ~2027-01-07 | Phase 2 | Dostarlimab, CAPEOX | Neoplasms, Colon | — | recruiting |
| 2026-11-26 Estimated 50% readout ~2027-02-09 | Phase 3 | Dostarlimab, Carboplatin, Paclitaxel | Neoplasms | — | active not recruiting |
Show all 80 trials · 75 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12-11 Estimated 50% readout ~2027-02-24 | Phase 3 | dTpa | Diphtheria-Tetanus-acellular Pertussis Vaccines | — | not yet recruiting |
| 2026-12-11 Estimated 50% readout ~2027-01-25 | Phase 2 | MMB | Neoplasms, Post-polycythemia Vera Myelofibrosis (Post-PV MF), Primary Myelofibrosis (PMF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Primary Myelofibrosis | — | active not recruiting |
| 2026-12-14 Estimated 50% readout ~2027-02-27 | Phase 3 | Investigational varicella vaccine, Marketed varicella vaccine, MMR vaccine | Chickenpox | — | recruiting |
| 2026-12-25 Estimated 50% readout ~2027-03-10 | Phase 3 | Investigational varicella vaccine_Lot 1, Investigational varicella vaccine_Lot 2, Investig | Chickenpox | — | recruiting |
| 2026-12-28 Estimated 50% readout ~2027-02-11 | Phase 2 | Niraparib | Ovarian Neoplasms, Breast Neoplasms | — | recruiting |
| 2026-12-31 Estimated 50% readout ~2027-01-30 | Phase 1 | GSK6097608, Dostarlimab, Cobolimab | Neoplasms | — | active not recruiting |
| 2027-01-12 Estimated 50% readout ~2027-02-26 | Phase 2 | Adjuvanted RSVPreF3 vaccine | Respiratory Syncytial Virus Infections | — | recruiting |
| 2027-01-15 Estimated 50% readout ~2027-03-31 | Phase 3 | FF/UMEC/VI, FF/VI | Asthma | — | recruiting |
| 2027-02-25 Estimated 50% readout ~2027-05-11 | Phase 3 | HFA-152a, HFA-134a | Asthma | — | not yet recruiting |
| 2027-03-01 Estimated 50% readout ~2027-03-31 | Phase 1 | TSR-022, Nivolumab, TSR-042 | Neoplasms | — | active not recruiting |
| 2027-03-09 Estimated 50% readout ~2027-04-23 | Phase 2 | Camlipixant | Irritable Bowel Syndrome | — | recruiting |
| 2027-03-10 Estimated 50% readout ~2027-04-24 | Phase 2 | MenABCWY vaccine | Meningitis, Meningococcal | — | active not recruiting |
| 2027-03-19 Estimated 50% readout ~2027-05-03 | Phase 2 | Momelotinib, Luspatercept | Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis | — | recruiting |
| 2027-04-22 Estimated 50% readout ~2027-06-06 | Phase 2 | Bepirovirsen | Hepatitis B | — | active not recruiting |
| 2027-04-23 Estimated 50% readout ~2027-06-07 | Phase 2 | RTS, S/AS01E vaccine | Malaria | — | recruiting |
| 2027-05-04 Estimated 50% readout ~2027-06-18 | Phase 2 | GSK3862995B | Bronchiectasis | — | recruiting |
| 2027-05-31 Estimated 50% readout ~2027-07-15 | Phase 2 | Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen | Chronic Hepatitis B Virus Infection, Hepatitis B | — | active not recruiting |
| 2027-05-31 Estimated 50% readout ~2027-07-15 | Phase 1/2 | Candidate UTI vaccine low dose formulation 1, Candidate UTI vaccine low dose formulation 2 | Urinary Tract Infections | — | recruiting |
| 2027-06-21 Estimated 50% readout ~2027-08-05 | Phase 1/2 | Mo-Rez, Dostarlimab, Bevacizumab | Tumours, Gynecological | — | recruiting |
| 2027-07-14 Estimated 50% readout ~2027-08-28 | Phase 2 | Momelotinib | Myelodysplastic Syndromes | — | recruiting |
| 2027-07-22 Estimated 50% readout ~2027-09-05 | Phase 2 | GSK3772701 600 mg, GSK3772701 900 mg, GSK3772701 150 mg | Malaria, Falciparum | — | not yet recruiting |
| 2027-07-26 Estimated 50% readout ~2027-09-09 | Phase 2 | VH4524184, Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC | HIV Infections | — | recruiting |
| 2027-08-02 Estimated 50% readout ~2027-09-16 | Phase 2 | GSK4532990 | Liver Diseases, Alcoholic | — | recruiting |
| 2027-08-23 Estimated 50% readout ~2027-11-06 | Phase 3 | HZ/su vaccine | Herpes Zoster | — | active not recruiting |
| 2027-08-27 Estimated 50% readout ~2027-11-10 | Phase 3 | BLU-5937 | Refractory Chronic Cough | — | recruiting |
| 2027-08-31 Estimated 50% readout ~2027-09-30 | Phase 1 | Remzistotug, Dostarlimab, Belrestotug | Neoplasms | — | active not recruiting |
| 2027-09-22 Estimated 50% readout ~2027-10-22 | Phase 1 | Mocertatug rezetecan | Solid Tumors, Neoplasms | — | recruiting |
| 2027-10-24 Estimated 50% readout ~2027-12-08 | Phase 2 | Dostarlimab | Neoplasms, Rectal | — | active not recruiting |
| 2027-10-26 Estimated 50% readout ~2027-12-10 | Phase 1/2 | GSK5458514 | Neoplasms, Prostate | — | recruiting |
| 2027-11-05 Estimated 50% readout ~2028-01-19 | Phase 3 | Ris-Rez, Topotecan | Neoplasms, Lung | — | recruiting |
| 2027-11-11 Estimated 50% readout ~2027-12-26 | Phase 1/2 | GSK5764227 | Gastrointestinal Neoplasms | — | recruiting |
| 2027-12-10 Estimated 50% readout ~2028-01-24 | Phase 1/2 | Ris-Rez, G-CSF | Sarcoma | — | not yet recruiting |
| 2028-01-05 Estimated 50% readout ~2028-03-20 | Phase 3 | Depemokimab | Asthma | — | recruiting |
| 2028-01-31 Estimated 50% readout ~2028-04-15 | Phase 3 | MMRVNS, MMRV | Measles | — | not yet recruiting |
| 2028-02-29 Estimated 50% readout ~2028-05-14 | Phase 3 | Mocertatug rezetecan, Paclitaxel, Doxorubicin | Neoplasms, Endometrial | — | recruiting |
| 2028-03-24 Estimated 50% readout ~2028-06-07 | Phase 3 | Efimosfermin Alfa | Non-alcoholic Fatty Liver Disease | — | recruiting |
| 2028-03-24 Estimated 50% readout ~2028-05-08 | Phase 1/2 | GSK5471713 | Neoplasms, Prostate | — | recruiting |
| 2028-03-29 Estimated 50% readout ~2028-06-12 | Phase 3 | Efimosfermin alfa | Non-alcoholic Fatty Liver Disease | — | recruiting |
| 2028-04-27 Estimated 50% readout ~2028-06-11 | Phase 2 | Low dose of iNTS-TCV, Full dose of iNTS-TCV, TYPHIBEV | Salmonella Infections | — | recruiting |
| 2028-05-30 Estimated 50% readout ~2028-08-13 | Phase 3 | IDRX-42, Sunitinib | Gastrointestinal Neoplasms | — | recruiting |
| 2028-06-30 Estimated 50% readout ~2028-09-13 | Phase 3 | Dostarlimab | Neoplasms, Head and Neck | — | recruiting |
| 2028-08-07 Estimated 50% readout ~2028-09-21 | Phase 1/2 | Pembrolizumab, Dostarlimab, Pemetrexed | Lung Cancer, Non-Small Cell | — | recruiting |
| 2028-09-15 Estimated 50% readout ~2028-10-30 | Phase 2 | GSK4527226 | Alzheimer's Disease | — | recruiting |
| 2028-09-28 Estimated 50% readout ~2028-11-12 | Phase 1/2 | GSK5460025 | Neoplasms, Colorectal, Neoplasms | — | recruiting |
| 2028-10-16 Estimated 50% readout ~2028-11-15 | Phase 1 | Ris-Rez, Cisplatin, Carboplatin | Neoplasms | — | recruiting |
| 2028-10-18 Estimated 50% readout ~2029-01-01 | Phase 3 | Belimumab | Lung Diseases, Interstitial | — | recruiting |
| 2028-10-31 Estimated 50% readout ~2028-12-15 | Phase 2 | AltSonflex1-2-3, Menveo, Infanrix hexa | Diarrhoea | — | not yet recruiting |
| 2028-12-06 Estimated 50% readout ~2029-02-19 | Phase 2/3 | Momelotinib, Glucocorticoids | VEXAS Syndrome | — | not yet recruiting |
| 2028-12-19 Estimated 50% readout ~2029-03-04 | Phase 3 | Depemokimab | Hypereosinophilic Syndrome | — | recruiting |
| 2029-01-01 Estimated 50% readout ~2029-03-17 | Phase 3 | CAB LA | HIV Infections | — | recruiting |
| 2029-01-24 Estimated 50% readout ~2029-03-10 | Phase 2 | Bepirovirsen | Hepatitis B | — | active not recruiting |
| 2029-02-06 Estimated 50% readout ~2029-03-08 | Phase 1 | GSK5533524 | Neoplasms | — | recruiting |
| 2029-02-28 Estimated 50% readout ~2029-04-14 | Phase 2 | Belantamab mafodotin, Dexamethasone, Bortezomib | Multiple Myeloma | — | not yet recruiting |
| 2029-03-19 Estimated 50% readout ~2029-06-02 | Phase 3 | Depemokimab | Asthma | — | not yet recruiting |
| 2029-03-19 Estimated 50% readout ~2029-06-02 | Phase 3 | Dostarlimab, CAPEOX, FOLFOX | Colonic Neoplasms, Neoplasms, Colon | — | recruiting |
| 2029-04-05 Estimated 50% readout ~2029-05-20 | Phase 1/2 | RSV/hMPV_V low dose vaccine, RSV/hMPV_V medium dose vaccine, RSV/hMPV_V high dose vaccine | Respiratory Syncytial Virus Infections+Metapneumovirus | — | not yet recruiting |
| 2029-05-17 Estimated 50% readout ~2029-07-31 | Phase 2/3 | Belimumab | Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic | — | recruiting |
| 2029-07-05 Estimated 50% readout ~2029-08-19 | Phase 1/2 | Ris-Rez, Ivonescimab | Solid Tumors | — | not yet recruiting |
| 2029-08-20 Estimated 50% readout ~2029-11-03 | Phase 3 | Depemokimab | Pulmonary Disease, Chronic Obstructive | — | recruiting |
| 2029-08-21 Estimated 50% readout ~2029-11-04 | Phase 3 | Depemokimab | Pulmonary Disease, Chronic Obstructive | — | recruiting |
| 2029-09-04 Estimated 50% readout ~2029-11-18 | Phase 3 | CAB ULA, RPV ULA, CAB LA | HIV Infections | — | not yet recruiting |
| 2029-09-24 Estimated 50% readout ~2029-11-08 | Phase 1/2 | GSK5926371 | Lymphoma, Non-Hodgkin | — | not yet recruiting |
| 2029-10-10 Estimated 50% readout ~2029-11-24 | Phase 1/2 | Oral CAB, IM CAB LA | HIV Infections | — | recruiting |
| 2029-11-02 Estimated 50% readout ~2030-01-16 | Phase 3 | Depemokimab | Pulmonary Disease, Chronic Obstructive | — | recruiting |
| 2029-12-03 Estimated 50% readout ~2030-01-17 | Phase 1/2 | Unconjugated belantamab antibody, Belantamab mafodotin, Unconjugated belantamab antibody a | Multiple Myeloma | — | recruiting |
| 2029-12-27 Estimated 50% readout ~2030-03-12 | Phase 3 | Belimumab | Connective Tissue Diseases | — | recruiting |
| 2030-03-31 Estimated 50% readout ~2030-05-15 | Phase 2 | Dostarlimab, Carboplatin, Paclitaxel | Neoplasms, Endometrial | — | recruiting |
| 2030-07-08 Estimated 50% readout ~2030-09-21 | Phase 3 | Depemokimab | Asthma | — | recruiting |
| 2030-08-21 Estimated 50% readout ~2030-11-04 | Phase 3 | Mocertatug rezetecan, Paclitaxel, Pegylated liposomal doxorubicin (PLD) | Ovarian Neoplasms | — | not yet recruiting |
| 2030-08-30 Estimated 50% readout ~2030-10-14 | Phase 2 | Belantamab mafodotin, Dexamethasone, Pomalidomide | Multiple Myeloma | — | recruiting |
| 2030-12-30 Estimated 50% readout ~2031-03-15 | Phase 3 | Fostemsavir, Dolutegravir (DTG)/ Lamivudine (3TC) | HIV Infections | — | not yet recruiting |
| 2031-04-28 Estimated 50% readout ~2031-07-12 | Phase 3 | Belantamab mafodotin, Lenalidomide, Dexamethasone | Multiple Myeloma, Newly Diagnosed Multiple Myeloma | — | recruiting |
| 2031-08-22 Estimated 50% readout ~2031-09-21 | Phase 1 | Belantamab mafodotin, Bortezomib, Dexamethasone | Multiple Myeloma | — | not yet recruiting |
| 2032-08-30 Estimated 50% readout ~2032-11-13 | Phase 3 | Velzatinib, Imatinib | Gastrointestinal Stromal Neoplasms | — | not yet recruiting |
| 2032-12-13 Estimated 50% readout ~2033-01-27 | Phase 2 | Belantamab mafodotin, Cyclophosphamide, Bortezomib | Amyloidosis | — | not yet recruiting |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
hold · target $58 (+15% upside) · 8 analysts
- 2026-01-06BarclaysEqual-Weight → Underweight
- 2024-11-12JefferiesBuy → Hold
- 2024-10-31GuggenheimBuy → Neutral
- 2024-07-08UBSBuy → Neutral
Competitors — Neoplasms
- LLYELI LILLY & Co$1094.4B · D3
- JNJJOHNSON & JOHNSON$617.4B · D0
- MRKMerck & Co., Inc.$318.8B · D3
- NVSEFNOVARTIS AG$292.0B · D3
- PFEPFIZER INC$142.2B · D3
- INCYINCYTE CORP$23.1B · D0
- DMRADamora Therapeutics, Inc.$1.8B · D6
- PRLDPrelude Therapeutics Inc$307M · D6
- PDSBPDS Biotechnology Corp$40M · D7
- AZNASTRAZENECA PLC— · D3
Recent news
- 2026-07-22FDA approves GSK’s Jideytro for previously treated ROS1-positive NSCLC - Bitget
- 2026-07-22GSK enters lung cancer drug market with early FDA nod for Jideytro - Reuters
- 2026-07-22GSK wins FDA nod for Jideytro lung cancer drug (GSK:NYSE) - Seeking Alpha
- 2026-07-22FDA Greenlights GSK’s First Lung Cancer Drug Ahead of Schedule - Benzinga
- 2026-07-22GSK (NYSE: GSK) gains early FDA approval for ROS1 lung cancer therapy - Stock Titan
- 2026-07-22GSK (GSK) Q4 2024 earnings summary - Quartr
- 2026-07-21GSK: Buy The Discount Before The Catalysts Close It (NYSE:GSK) - Seeking Alpha
- 2026-07-21By mid-2027, analysts expect £6,000 in GSK shares to be worth… - Yahoo Finance UK
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.